Monitoring MDSC – A Hurdle to Immune Checkpoints Inhibitors

Back to the list Next article Previous article

November 9, 2020

Damien Montamat-Sicotte, Laetitia Cortes, Virginia Litwin, Henry Hepburne-Scott, Phoebe Bonner

CellCarta’s poster discusses the challenges of monitoring myeloid-derived suppressor cells (MDSCs), which can hinder the effectiveness of immune checkpoint inhibitors.

The study introduces a standardized method for identifying MDSCs using HLA-DR expression levels to distinguish between low and high MDSC populations. This approach was validated in a clinical study with melanoma patients undergoing pembrolizumab treatment, showing a correlation between high MDSC levels and reduced survival rates.

The MDSC phenotyping assay developed by CellCarta offers a reliable tool for assessing MDSC impact on immunotherapy and improving treatment strategies.

As presented in SITC 2020